Q-omics provides the consensus-scored MRPL46 profile across patient tissues and cancer cell-line models. MRPL46 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPL46 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, MRPL46 protein abundance shows 20,065 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KICH, and LSCC as cancer lineages where MRPL46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL46 survival associations across molecular data types. MRPL46 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL46 RNA expression–survival associations across cancer types. High MRPL46 expression shows unfavorable associations in UVM and MESO, but favorable associations in KIRC, READ, OV and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPL46 RNA expression.
This table summarizes MRPL46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL46 shows lower tumor expression in KICH, KIRP and UCEC and higher tumor expression in LUSC, STAD and LUAD. The KICH box plot shows higher MRPL46 RNA expression in normal versus tumor tissue (log2 FC = −0.425, t-test p < 0.001).
This table shows molecular features associated with MRPL46 in patient tissues and cancer cell lines. In patient samples, MRPL46 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL46 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
